PMID- 15222660
OWN - NLM
STAT- MEDLINE
DCOM- 20041015
LR  - 20191210
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 24
IP  - 6
DP  - 2004 Jun
TI  - Achieving target antifactor Xa activity with a heparin protocol based on sex, 
      age, height, and weight.
PG  - 713-9
AB  - STUDY OBJECTIVES: To develop and validate an improved unfractionated heparin 
      (UFH) dosage protocol, using antifactor Xa levels as the outcome variable. 
      DESIGN: Prospective case series. SETTING: A 625-bed, adults-only private, 
      tertiary care teaching hospital. PATIENTS: Three hundred seventy-two patients 
      receiving UFH for eight different indications were in the protocol derivation 
      group. One hundred ninety-seven patients were in the final validation group. 
      Intervention. Variables that predicted successful UFH treatment were determined 
      by analysis of variance and regression. MEASUREMENTS AND MAIN RESULTS: Sex, age, 
      height, weight, UFH dosage, and antifactor Xa levels were variables. A regression 
      model using sex, age, height, and weight was superior to a weight-only model in 
      predicting UFH dosage. Target-range antifactor Xa levels were achieved with the 
      new protocol in 122 (87%) of 140 patients within 24 hours of start of therapy. 
      CONCLUSION: A UFH dosage protocol based on patient sex, age, height, and weight 
      produced improved initial target antifactor Xa levels compared with a 
      weight-based protocol. The protocol is computerized and easy to apply.
FAU - Rosborough, Terry K
AU  - Rosborough TK
AD  - Medical Education Department, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota 55407, USA.
FAU - Shepherd, Michele F
AU  - Shepherd MF
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Validation Study
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*administration & dosage/blood
MH  - Body Height
MH  - *Body Weight
MH  - Clinical Protocols
MH  - Drug Monitoring/methods/*standards
MH  - *Factor Xa Inhibitors
MH  - Female
MH  - Heparin/*administration & dosage/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Partial Thromboplastin Time
MH  - Prospective Studies
MH  - Sex Factors
EDAT- 2004/06/30 05:00
MHDA- 2004/10/16 09:00
CRDT- 2004/06/30 05:00
PHST- 2004/06/30 05:00 [pubmed]
PHST- 2004/10/16 09:00 [medline]
PHST- 2004/06/30 05:00 [entrez]
AID - 10.1592/phco.24.8.713.36067 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2004 Jun;24(6):713-9. doi: 10.1592/phco.24.8.713.36067.